食管切除术后患者报告反流的预测因素
这项前瞻性临床研究纳入110例食管切除术后患者,记录患者报告的反流症状,旨在确定预测因素并评估保留幽门是否具有保护作用。多变量线性回归显示,较短的胃管长度(P = .02)和未接受围手术期放化疗(P = .01)是患者报告反流较差的显著预测因素。接受幽门引流与接受肉毒杆菌毒素治疗的患者之间无显著差异。
要点
- 较短的胃管长度与更差的患者报告反流显著相关(P = .02)。
- 未接受围手术期放化疗是患者报告反流的显著预测因素(P = .01)。
- 保留幽门(肉毒杆菌毒素)与幽门引流在患者报告反流上无显著差异。
核心结论
- 未接受围手术期放化疗和较短的胃管是食管切除术后患者报告反流的预测因素。
- 保留幽门似乎不影响患者报告的反流,但接受肉毒杆菌毒素的患者较少,需进一步客观研究确认。
研究设计与样本
- 前瞻性临床研究,记录2015年8月至2018年7月食管切除术后患者报告的反流。
- 纳入标准:传统后纵隔胃管创建后至少6个月、完成至少1份反流问卷、幽门接受临时(≥100 IU肉毒杆菌毒素)或永久(幽门肌切开术或幽门成形术)处理。
- 共110例患者符合纳入标准,中位年龄65岁,88例(80%)为男性。
主要发现
- 肉毒杆菌毒素用于15例(14%),幽门肌切开术88例(80%),幽门成形术7例(6%)。
- 胸部吻合78例(71%),颈部吻合32例(29%)。
- 105/110例(95%)因恶性疾病行食管切除术,78/110例(71%)接受围手术期放化疗。
- 多变量线性回归分析显示,患者报告反流在胃管较短(P = .02)和未接受围手术期放化疗(P = .01)的患者中显著更差。
- 接受幽门引流与接受肉毒杆菌毒素治疗的患者之间无显著差异。
临床怎么用
- 对于食管切除术后患者,胃管较短或未接受围手术期放化疗者可能需关注反流症状。
- 保留幽门(肉毒杆菌毒素)未显示对患者报告反流有保护作用,选择幽门处理方式时可综合考虑。
局限性
- 接受肉毒杆菌毒素的患者较少。
- 需要进一步客观研究确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patient-reported reflux is among the most common symptoms after esophagectomy. This study aimed to determine predictors of patient-reported reflux and to ascertain whether a preserved pylorus would protect patients from symptomatic reflux. METHODS: A prospective clinical study recorded patient-reported reflux after esophagectomy from August 2015 to July 2018. Eligible patients were at least 6 months from creation of a traditional posterior mediastinal gastric conduit, had completed at least 1 reflux questionnaire, and had the pylorus treated either temporarily (≥100 IU Botox [onabotulinumtoxinA]) or permanently (pyloromyotomy or pyloroplasty). RESULTS: Of the 110 patients meeting inclusion criteria, the median age was 65 years, and 88 of the 110 (80%) were male. Botox was used in 15 (14%) patients, pyloromyotomy in 88 (80%), and pyloroplasty in 7 (6%). A thoracic anastomosis was performed in 78 (71%) patients, and a cervical anastomosis was performed in 32 (29%). Esophagectomy was performed for malignant disease in 105 of 110 (95%), and 78 of 110 (71%) patients were treated with perioperative chemoradiation. Multivariable linear regression analysis revealed that patient-reported reflux was significantly worse in patients with shorter gastric conduit lengths (P = .02) and in patients who did not undergo perioperative chemoradiation (P = .01). No significant difference was found between patients treated with pyloric drainage and those treated with Botox. CONCLUSIONS: The absence of perioperative chemoradiation therapy and a shorter gastric conduit were predictors of patient-reported reflux after esophagectomy. Although few patients had Botox, preservation of the pylorus did not appear to affect patient-reported reflux. Further objective studies are needed to confirm these findings.
引用
- Hasan IS, Mahajan N, Viehman J, et al. Predictors of Patient-Reported Reflux After Esophagectomy. Ann Thorac Surg. 2020. PMID: 32454018. doi:10.1016/j.athoracsur.2020.03.127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。